These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 19102722)

  • 1. Drug-diagnostic codevelopment strategies: FDA and industry dialog at the 4th FDA/DIA/PhRMA/PWG/BIO Pharmacogenomics Workshop.
    Hinman L; Spear B; Tsuchihashi Z; Kelly J; Bross P; Goodsaid F; Kalush F
    Pharmacogenomics; 2009 Jan; 10(1):127-36. PubMed ID: 19102722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The drug diagnostic co-development concept paper: commentary from the 3rd FDA-DIA-PWG-PhRMA-BIO Pharmacogenomics Workshop.
    Hinman LM; Huang SM; Hackett J; Koch WH; Love PY; Pennello G; Torres-Cabassa A; Webster C
    Pharmacogenomics J; 2006; 6(6):375-80. PubMed ID: 16652120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4th US FDA-Drug Information Association pharmacogenomics workshop, held 10-12 December, 2007.
    Frueh FW; Salerno RA; Lesko LJ; Hockett RD
    Pharmacogenomics; 2009 Jan; 10(1):111-5. PubMed ID: 19102720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA-PWG-PhRMA-DruSafe Workshop.
    Lesko LJ; Salerno RA; Spear BB; Anderson DC; Anderson T; Brazell C; Collins J; Dorner A; Essayan D; Gomez-Mancilla B; Hackett J; Huang SM; Ide S; Killinger J; Leighton J; Mansfield E; Meyer R; Ryan SG; Schmith V; Shaw P; Sistare F; Watson M; Worobec A
    J Clin Pharmacol; 2003 Apr; 43(4):342-58. PubMed ID: 12723455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and regulatory strategies for drug and diagnostic co-development.
    Hinman LM; Carl KM; Spear BB; Salerno RA; Becker RL; Abbott BM; Kelly JF; Mansfield E; Katz RG; Harper C; Day SP; Pacanowski MA; Pignato W
    Pharmacogenomics; 2010 Dec; 11(12):1669-75. PubMed ID: 21142909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three years of promise, proposals, and progress on optimizing the benefit/risk of medicines: a commentary on the 3rd FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop.
    Salerno RA; Lesko LJ
    Pharmacogenomics J; 2006; 6(2):78-81. PubMed ID: 16402087
    [No Abstract]   [Full Text] [Related]  

  • 7. Developing the evidence base for applying pharmacogenomics: proceeds from DIA Workshop IV--Breakout Session 1.
    Armstrong M; Bromley C; Cohen N; Hunt CM; O'Neill R; Power A
    Pharmacogenomics; 2009 Jan; 10(1):117-25. PubMed ID: 19102721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with voluntary and required genomic data submissions to the FDA: summary report from track 1 of the third FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop.
    Frueh FW; Rudman A; Simon K; Gutman S; Reed C; Dorner AJ
    Pharmacogenomics J; 2006; 6(5):296-300. PubMed ID: 16568150
    [No Abstract]   [Full Text] [Related]  

  • 9. Generating and weighing evidence in drug development and regulatory decision making: 5th US FDA-DIA workshop on pharmacogenomics.
    Shaw PM; Zineh I
    Pharmacogenomics; 2010 Dec; 11(12):1629-35. PubMed ID: 21142905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enabling pharmacogenomic clinical trials through sampling.
    Warner A; Nelsen A; Bhathena A; Fitzgerald K; Gilardi S; Kelso E; Knoppers B; McLeod HL; Nelson R; Uyama Y; Weisman J; Rudman A
    Pharmacogenomics; 2010 Dec; 11(12):1649-54. PubMed ID: 21142907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Learning from product labels and label changes: how to build pharmacogenomics into drug-development programs.
    Surh LC; Pacanowski MA; Haga SB; Hobbs S; Lesko LJ; Gottlieb S; Papaluca-Amati M; Patterson SD; Hughes AR; Kim MJ; Close SL; Mosteller M; Zineh I; Dechairo B; Cohen NA
    Pharmacogenomics; 2010 Dec; 11(12):1637-47. PubMed ID: 21142906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Companion diagnostics: emerging strategies and issues in pharmaceutical development.
    Thomas J; Stratton E; Keppens M
    Expert Rev Mol Diagn; 2012 Jul; 12(6):561-3. PubMed ID: 22845476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cautious welcome for FDA pharmacogenomics guidance.
    Katsnelson A;
    Nat Biotechnol; 2005 May; 23(5):510. PubMed ID: 15877053
    [No Abstract]   [Full Text] [Related]  

  • 14. Fit-for-purpose pharmacogenomic biomarkers in drug development: a project team case study with 'what-ifs'.
    Surh LC; Lesko LJ; Hobbs S; Gutman S; Minasian LM; Della Pasqua OE; Austin MJ; Lu K
    Pharmacogenomics; 2009 Jan; 10(1):137-47. PubMed ID: 19102723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designing pharmacogenomic studies to be fit for purpose.
    Burns DK; Hughes AR; Power A; Wang SJ; Patterson SD
    Pharmacogenomics; 2010 Dec; 11(12):1657-67. PubMed ID: 21142908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomics in Drug Development and Regulatory Decision-making: the Genomic Data Submission (GDS) Proposal.
    Salerno RA; Lesko LJ
    Pharmacogenomics; 2004 Jan; 5(1):25-30. PubMed ID: 14683418
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacogenomics in the assessment of therapeutic risks versus benefits: inside the United States Food and Drug Administration.
    Zineh I; Pacanowski MA
    Pharmacotherapy; 2011 Aug; 31(8):729-35. PubMed ID: 21923598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of ADME pharmacogenomics in early clinical trials: perspective of the Industry Pharmacogenomics Working Group (I-PWG).
    Tremaine L; Brian W; DelMonte T; Francke S; Groenen P; Johnson K; Li L; Pearson K; Marshall JC
    Pharmacogenomics; 2015 Dec; 16(18):2055-67. PubMed ID: 26616152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoliberal technocracy: explaining how and why the US Food and Drug Administration has championed pharmacogenomics.
    Hogarth S
    Soc Sci Med; 2015 Apr; 131():255-62. PubMed ID: 25661300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
    Tazawa Y
    Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.